Bisphosphonate incadronate prevents total gastrectomy-induced osteopenia in rats.
Total gastrectomy (GX) leads to osteopenia. We examined the effects of bisphosphonate incadronate (INC), a potent inhibitor of bone resorption, on bone characteristics in rats that underwent total GX. Male Wistar rats were divided into four groups: (1) sham-operation (n=10); (2) total GX control (n=6); (3) total GX with 0.3 mg kg(-1) day(-1) oral administration of INC (n=7); and (4) total GX with 3.0 mg kg(-1) day(-1) oral administration of INC (n=7). Total GX significantly impaired bone mineral density; these effects were prevented by treatment with INC. Similarly, in GX control rats, morphometrical changes of femoral metaphysis stained with Villanueva's and Villanueva-Goldner's: bone volume, tissue volume, mineral apposition rate, labeled/bone surface, bone formation rate, osteoid volume, mineralization lag time as well as serum osteocalcin, and urinary deoxypyridinoline demonstrated simultaneous existence of both osteomalacia and osteopenia; these impairments were also prevented by INC. However, GX-induced decrease in serum levels of calcium as well as 25-hydroxyvitamin D/24,25-dihydroxyvitamin D and the increase in 1,25-dihydroxyvitamin D were not prevented by administration of INC. These results enhance the understanding of the unique pathophysiology of both osteomalacia and osteoporosis induced by total GX and suggest the possibility of using INC as preventive therapy for osteopenia in GX-treated patients.